Self-report and laboratory measures of impulsivity in patients with schizophrenia or schizoaffective disorder and healthy controls

Nolan, Karen; D’Angelo, Debra; Hoptman, Matthew J.

doi:10.1016/j.psychres.2010.10.032

Cited by 66 publications

(51 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The previous findings with schizophrenia are more mixed. Schizophrenia patients have reported higher levels of impulsivity on the BIS-11 than controls (Nolan et al, 2011), which is in the direction we found, although it was not significant in our sample. Our findings are consistent with a previous study of the BART that showed significantly less risk taking in schizophrenia patients than controls (Cheng et al, 2012).…”

contrasting

confidence: 49%

Impulsivity and Risk Taking in Bipolar Disorder and Schizophrenia

Reddy

Lee

Davis

et al. 2013

Neuropsychopharmacol

166

112

View full text Add to dashboard Cite

Impulsive risk taking contributes to deleterious outcomes among clinical populations. Indeed, pathological impulsivity and risk taking are common in patients with serious mental illness, and have severe clinical repercussions including novelty seeking, response disinhibition, aggression, and substance abuse. Thus, the current study seeks to examine self-reported impulsivity (Barratt Impulsivity Scale) and performance-based behavioral risk taking (Balloon Analogue Risk Task) in bipolar disorder and schizophrenia. Participants included 68 individuals with bipolar disorder, 38 with schizophrenia, and 36 healthy controls. Self-reported impulsivity was elevated in the bipolar group compared with schizophrenia patients and healthy controls, who did not differ from each other. On the risk-taking task, schizophrenia patients were significantly more risk averse than the bipolar patients and controls. Aside from the diagnostic group differences, there was a significant effect of antipsychotic (AP) medication within the bipolar group: bipolar patients taking AP medications were more risk averse than those not taking AP medications. This difference in risk taking because of AP medications was not explained by history of psychosis. Similarly, the differences in risk taking between schizophrenia and bipolar disorder were not fully explained by AP effects. Implications for clinical practice and future research are discussed.

show abstract

contrasting

confidence: 49%

Impulsivity and Risk Taking in Bipolar Disorder and Schizophrenia

Reddy

Lee

Davis

et al. 2013

Neuropsychopharmacol

166

112

View full text Add to dashboard Cite

show abstract

“…A significant neurobiological mechanism underlying substance use and addiction is reduced DA function in the PFC (Koob and Volkow, 2010;Volkow et al, 2009). Deficits in PFC DA function have also been reported in schizophrenia and ADHD (Russell, 2002;Volk and Lewis, 2010), disorders that are also characterized by impulsive behaviors (American Psychiatric Association, 2000; Kaladjian et al, 2011;Nolan et al, 2011).…”

Section: Discussionmentioning

confidence: 99%

Catecholamine receptors differentially mediate impulsive choice in the medial prefrontal and orbitofrontal cortex

et al. 2012

View full text Add to dashboard Cite

Impulsivity is characteristic of several mental health disorders and is largely mediated by the prefrontal cortex subregions: the medial prefrontal cortex (mPFC) and the orbitofrontal cortex (OFC). Dopamine (DA) and norepinephrine (NE) are known to modulate activity of the prefrontal cortex, however their direct role in impulsive choice is not known. The aim of the present study was to investigate the effect of microinjecting DA or NE compounds in the mPFC or OFC on impulsive choice as measured by a delayed reinforcement (DR) task in male Wistar Kyoto rats. Following training in the DR task, rats were pretreated with DA D(1) and D(2) receptor antagonists (SCH23390 3 μg/side, raclopride 3 or 6 μg/side) or NE α(1) and α(2) receptor agonists (phenylephrine 0.1 or 0.3 μg/side, guanfacine 1 or 3 μg/side, respectively) into the mPFC or OFC and the effect on impulsive behavior was assessed. Pretreatment with raclopride into the mPFC or OFC significantly increased impulsive choice, however only pretreatment with SCH23390 into the mPFC, and not the OFC, significantly increased impulsive choice. Pretreatment with the NE receptor agonists had no effect on impulsive choice. This study suggests that DA receptors, but not NE receptors, differentially mediate impulsive choice in sub-regions of the prefrontal cortex.

show abstract

“…There is evidence that subjective (i.e., self-report) measures of self-control positively correlate with more objective (i.e., behavioral) measures of self-control (39)(40)(41). The BSC consisted of 13 items.…”

Section: Methodsmentioning

confidence: 99%